Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma
Title
Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma
Creator
Kushner BH; Kramer K; Modak S; Cheung NK
Identifier
Publisher
Cancer
Date
2005
Subject
U.S. Gov't; PedPal Lit; Non-U.S. Gov't Research Support; 15 patients had stable disease; 2 (n=3); 2 (n=9); 22 (n=1 patient); 3 (n=1); 4 (n=2(TRUNCATED); 4 (n=6); 7 (n=1 patient); 7 were not evaluable for response because of concurrent radiotherapy; Adolescent Adult Antineoplastic Agents; although they did not have progressive disease (PD) after receiving 1 (n=10); and 1 patient had a major response. Twenty-one patients had PD after 1 (n=3; and myelosuppressive effects were readily managed. Hospitalizations were limited to three patients with bacteremia. Twenty-three patients had a change in therapy; diarrheal; Intravenous Male Nervous System Neoplasms/drug therapy Neuroblastoma/drug therapyPalliative Care Quality of Life Research Support; or 24 (n=1) courses. The most common reasons for changing treatment were to intensify retrieval therapy or to pursue immunotherapy. Of those 23 patients; P.H.S. Retrospective Studies Treatment Outcome; Phytogenic/administration & dosage/adverse effects Camptothecin/administration & dosage/adverse effects/analogs & derivatives Child Child; Preschool Female Humans Infusions
Description
2005
Rights
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
Journal Article
Citation List Month
Backlog
URL Address
Citation
Kushner BH; Kramer K; Modak S; Cheung NK, “Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma,” Pediatric Palliative Care Library, accessed February 15, 2025, https://pedpalascnetlibrary.omeka.net/items/show/13804.